Recently, Suzhou Xinmaide Medical Device Technology Co., Ltd. completed the A round of financing, which was exclusively invested by Hongyuan Capital. This is Xinmaide’s first external financing since its establishment. The proceeds will be used for the construction of the company’s pulmonary drug delivery and nasal drug delivery technology platforms, the upgrade of industrialized manufacturing centers, and team expansion.
Founded in 2016, Xinmaide is committed to the design, development, and manufacture of complex drug delivery devices, as well as the development of drug-device combination products. Relying on its technology platforms such as pulmonary drug delivery and nasal drug delivery, Syntec has developed single-dose capsule DPI devices, multi-dose blister DPI devices, soft mist inhalation devices and multi-power nasal spray devices, etc. The field covers the delivery of drugs for diseases such as asthma, chronic obstructive pulmonary disease (COPD), nose and brain.
Since its establishment, Xinmaide has broken through the barriers of technical patents and has reached commercial development cooperation with many large listed pharmaceutical companies in Asia. It is the manufacturer with the largest number of inhalation drug delivery devices in China. From high-end imitation inhalation devices to innovative IP design devices, Synmatech has completely independent intellectual property rights, and has achieved technological breakthroughs in commercialized mass production of medical drug delivery-grade silicon chip design and atomization chip modules.
Mr. Zhao Guangtao, founder and chairman of Xinmaide, said: “Asthma, COPD, rhinitis and other respiratory diseases are an important class of chronic diseases in my country, with a large patient base, inhaled preparations mainly rely on a few imported therapeutic drugs, and the patient’s medication burden is heavy. , there is an unmet medical need. Neomed is committed to utilizing the technological innovation of drug delivery devices to maximize the clinical efficacy of drugs and provide patients with more high-quality and accessible treatment options. We are very honored to be awarded with Hongyuan The trust and strong support of capital. In the future, with the help of capital, the company will continue to uphold our entrepreneurial philosophy and original intention, focus on the unmet clinical needs of China, deepen the field of inhalation preparations, and improve product accessibility and affordability , to benefit more patients with chronic respiratory diseases.”
Dr. Zhu Qingsheng, founding partner of Hongyuan Capital, said: “Globally, inhalation drug delivery is very difficult in both new product development and generic drug consistency evaluation, and the barriers of drug delivery devices in drug-device combination products have been difficult to break through. It is very encouraging that Meade is the first local company in China that can break through technical barriers in this field and successfully pass the BE consistency evaluation. Hongyuan Capital is very pleased to cooperate with New Meade to help promote the innovation of inhaled drug delivery preparations in all aspects. Together with localization, it will bring more accessible treatments to Chinese patients.”
media coverage
The investment community Yiou Venture State
This article is reproduced from: https://readhub.cn/topic/8jDVZHc4TCU
This site is for inclusion only, and the copyright belongs to the original author.